Clinical Trials
8
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
A Phase I/IIa Clinical Trial to Investigate BVAC-E6E7 in Subjects with HPV Positive HNSCC.
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC)HPV (human Papillomavirus)-Associated CarcinomaHPV Positive Oropharyngeal Squamous Cell Carcinoma
- Interventions
- Biological: BVAC-E6E7 (low level)Biological: BVAC-E6E7 (high level)Biological: BVAC-E6E7 (RP2D)
- First Posted Date
- 2025-01-29
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- Cellid Co., Ltd.
- Target Recruit Count
- 37
- Registration Number
- NCT06797986
Immunogenicity and Safety of AdCLD-CoV19-1 OMI As a Booster: a COVID-19 Preventive Vaccine in Healthy Volunteers
- Conditions
- COVID-19Vaccines
- Interventions
- Biological: Comirnaty Bivalent 0.1mg/mL (tozinameran and riltozinameran)Biological: AdCLD-CoV19-1 OMI
- First Posted Date
- 2023-08-15
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Cellid Co., Ltd.
- Target Recruit Count
- 4000
- Registration Number
- NCT05993325
- Locations
- 🇰🇷
Dong-a University Hospital, Busan, Korea, Republic of
🇰🇷Kyungpook National University Hospital, Daegu, Korea, Republic of
🇰🇷Chungnam National University Hospital, Daejeon, Korea, Republic of
Safety and Immunogenicity of AdCLD-CoV19-1 OMI as a Booster: A SARS-CoV-2 (COVID-19) Preventive Vaccine
- Conditions
- VaccinesCOVID-19
- First Posted Date
- 2022-10-12
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- Cellid Co., Ltd.
- Target Recruit Count
- 320
- Registration Number
- NCT05576623
- Locations
- 🇰🇷
Hallym University Dongtan Sacred Heart Hospital, Gyeonggi-do, Korea, Republic of
🇰🇷Korea University Ansan Hospital, Gyeonggi-do, Korea, Republic of
🇰🇷The Catholic University of Korea ST. Vincent's Hospital, Gyeonggi-do, Korea, Republic of
Safety and Immunogenicity of COVID-19 Vaccine, AdCLD-CoV19-1
- Conditions
- COVID-19Vaccines
- First Posted Date
- 2022-08-30
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Cellid Co., Ltd.
- Target Recruit Count
- 4
- Registration Number
- NCT05520970
- Locations
- 🇰🇷
Korea University Ansan Hospital, Ansan, Korea, Republic of
🇰🇷Catholic University Seoul St.Mary's Hospital, Seoul, Korea, Republic of
🇰🇷Hallym University Kangnam Sacred Heart Hospital, Seoul, Korea, Republic of
Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers
- Conditions
- Covid19
- First Posted Date
- 2021-09-17
- Last Posted Date
- 2023-07-28
- Lead Sponsor
- Cellid Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT05047692
- Locations
- 🇰🇷
Korea University Ansan Hospital, Ansan, Province, Korea, Republic of
🇰🇷The Catholic University of Korea, ST. Vincent's Hospital, Suwon, Province, Korea, Republic of
🇰🇷Korea University Guro Hospital, Seoul, State, Korea, Republic of
- Prev
- 1
- 2
- Next